Research Progress of Upadacitinib in the Treatment of Crohn’s Disease
10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.2023.0606
- VernacularTitle:乌帕替尼治疗克罗恩病的研究进展
- Author:
Hui-feng FAN
1
;
Xiu-yan ZHOU
2
Author Information
1. Second Clinical Medical College， Shanxi Medical University，Taiyuan 030000， China
2. Department of Gastroenterology，The Second Hospital of Shanxi Medical University， Taiyuan 030000， China
- Publication Type:Review
- Keywords:
upadacitinib;
Crohn’s Disease;
pathogenesis;
curative effect;
drug safety
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2023;44(6):925-930
- CountryChina
- Language:Chinese
-
Abstract:
Crohn’s Disease （CD） is a destructive， relapsing and remitting chronic inflammatory bowel disease that usually progresses to irreversible intestinal structural and functional changes， such as intestinal lumen stenosis， fistula formation and perianal lesions， severely affecting the quality of life of patients. This review summarized the research progress on the mechanism， clinical application and safety of upadacitinib in the treatment of CD. Upadacitinib can increase the clinical remission and endoscopic response rates in patients with CD， improve the long-term outcome of CD patients and provide a new idea for the treatment of CD patients by using biological agents.
